156 related articles for article (PubMed ID: 38548067)
1. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
J Hepatol; 2024 Mar; ():. PubMed ID: 38548067
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
Kim BK; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Lin T; Tu XM; Bergstrom J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
J Hepatol; 2022 Dec; 77(6):1482-1490. PubMed ID: 35973577
[TBL] [Abstract][Full Text] [Related]
3. Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
Qi S; Wei X; Zhao J; Wei X; Guo H; Hu J; WuYun Q; Pan CQ; Zhang N; Zhang J
J Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38686620
[TBL] [Abstract][Full Text] [Related]
4. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
5. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
[TBL] [Abstract][Full Text] [Related]
6. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Tamaki N; Imajo K; Sharpton S; Jung J; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
Hepatology; 2022 Mar; 75(3):661-672. PubMed ID: 34496054
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
[TBL] [Abstract][Full Text] [Related]
9. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.
Ichikawa T; Oba H; Owada M; Watanabe K; Yoshimura T; Fuchigami A; Nakamura A
JGH Open; 2023 Dec; 7(12):959-965. PubMed ID: 38162848
[TBL] [Abstract][Full Text] [Related]
11. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
12. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
13. M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis.
Imajo K; Saigusa Y; Kobayashi T; Nagai K; Nishida S; Kawamura N; Doi H; Iwaki M; Nogami A; Honda Y; Kessoku T; Ogawa Y; Kirikoshi H; Yasuda S; Toyoda H; Hayashi H; Kokubu S; Utsunomiya D; Takahashi H; Aishima S; Kim BK; Tamaki N; Saito S; Yoneda M; Loomba R; Nakajima A
Hepatol Res; 2023 Sep; 53(9):844-856. PubMed ID: 37237426
[TBL] [Abstract][Full Text] [Related]
14. NIS2+
Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
[TBL] [Abstract][Full Text] [Related]
15. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
16. A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.
Mittal N; Siddiqi H; Madamba E; Richards L; Bettencourt R; Ajmera V; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59(12):1571-1578. PubMed ID: 38586922
[TBL] [Abstract][Full Text] [Related]
17. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).
Albert SG; Wood EM
J Diabetes Complications; 2024 Jul; 38(7):108777. PubMed ID: 38788522
[TBL] [Abstract][Full Text] [Related]
18. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
[TBL] [Abstract][Full Text] [Related]
19. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
20. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
Taru MG; Tefas C; Neamti L; Minciuna I; Taru V; Maniu A; Rusu I; Petrushev B; Procopciuc LM; Leucuta DC; Procopet B; Ferri S; Lupsor-Platon M; Stefanescu H
PLoS One; 2024; 19(5):e0303971. PubMed ID: 38781158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
